Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Clindamycin
Ceva Santé Animale
QJ01FF01
Clindamycin
150 mg/tablet
Chewable tablet
POM: Prescription Only Medicine as defined in relevant national legislation
Dogs
clindamycin
Antibacterial
Authorised
2016-04-22
Health Products Regulatory Authority 06 May 2021 CRN009XNY Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Zodon 150 mg chewable tablets for dogs. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains: ACTIVE SUBSTANCE: Clindamycin (as hydrochloride) 150 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Chewable tablet Clover-shaped scored beige tablet. The tablet can be divided into four equal parts. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Dogs. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES - For the treatment of infected wounds and abscesses, and oral cavity infections including periodontal disease, caused by or associated with _Staphylococcus _spp_., Streptococcus _spp_. (_except _Streptococcus faecalis), Bacteroides _spp_., Fusobacterium _ _necrophorum, _and _Clostridium perfringens. _ - For the treatment of superficial pyoderma associated with _Staphylococcus pseudintermedius_. - For the treatment of osteomyelitis, caused by _Staphylococcus aureus. _ 4.3 CONTRAINDICATIONS Do not use in cases of hypersensitivity to the active substance or to any of the excipients or to lincomycin. Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestionof clindamycin by these species may result in severe gastro-intestinal disturbance. 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES None. 4.5 SPECIAL PRECAUTIONS FOR USE Special precautions for use in animals The chewable tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals. Use of the product should be based on susceptibility testing of the bacteria isolated from the animal. Official and local antimicrobial policies should be taken into account when the product is used. Use of the product deviating from the instructions given in the SPC may increase the prevalence of bacteria resistant to clindamycin and may decrease the effectiveness of treatment with lincomycin or macrolide antimicrobials d Read the complete document